Five-Year Resistance Trends Of Bacterial Isolates In Kigali, Rwanda by Carroll, Makeda Aminah
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses School of Public Health
January 2015
Five-Year Resistance Trends Of Bacterial Isolates In
Kigali, Rwanda
Makeda Aminah Carroll
Yale University, makedacarroll@yahoo.com
Follow this and additional works at: http://elischolar.library.yale.edu/ysphtdl
This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an authorized administrator of EliScholar – A Digital Platform for
Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Carroll, Makeda Aminah, "Five-Year Resistance Trends Of Bacterial Isolates In Kigali, Rwanda" (2015). Public Health Theses. 1035.
http://elischolar.library.yale.edu/ysphtdl/1035
 1
Five-year resistance trends of bacterial isolates in Kigali, Rwanda 
Makeda Carroll, Debbie Humphries, James Childs, Onyema Ogbuagu 
  
 2
Abstract 
Antimicrobial resistance (AMR), the phenomenon of decreased sensitivity to pharmaceutical 
agents that kill or inhibit the growth of bacterial pathogens, is a serious threat to public health 
worldwide. Many countries, including Rwanda, lack current information on antibiotic sensitivity 
profiles that would greatly aide clinicians and policy-makers. The current study aims to describe 
the time trends of antibiotic sensitivity for the isolates of six different bacterial pathogens from 
patients at King Faisal Hospital in Kigali, Rwanda and to make inference about future patterns of 
drug resistance in the study setting, to guide physicians in their prescribing practices and 
provide baseline data for future interventions. This was a retrospective observational study that 
involved data collection of the frequency and antimicrobial sensitivity patterns of bacterial 
organisms isolated from cultures of clinical specimens collected from patients at the King Faisal 
Hospital in Kigali, Rwanda. Data were collected over a five-year period from January 1, 2009 to 
December 31, 2013. Cochran-Armitage test and Somers’ D statistic were used to determine 
trends in antibiotic sensitivity over time. Analysis found that the majority of isolates collected 
over the study period were of E. coli (46.7%). Amongst the gram-negative species, Colistin 
consistently elicited the highest average annual antibiotic sensitivity. Notably, Acinetobacter 
spp. showed the greatest resistance to all antibiotics, relative to other species of its group. 
Vancomycin showed the greatest activity against gram-positive bacteria. Trend analysis 
determined that Imipenem and Pipercillin demonstrated negative annual sensitivity trends 
more often than any other antibiotics. AMR trends showed that decreased bacterial sensitivity 
to Imipenem and Pipercillin is increasing over time and limits the usefulness of the drugs for 
empiric therapy of gram infections. 
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Introduction: 
Antimicrobial resistance is the phenomenon of decreased sensitivity to pharmaceutical agents 
that kill or inhibit the growth of bacterial pathogens [1]. It is becoming increasingly problematic as the 
proportion of pathogens, including Staphylococcus spp., Klebsiella spp., and E. coli, continues to increase 
relative to those which are still drug sensitive.  Rapid emergence of antimicrobial resistance (AMR) 
seriously threatens the progress we have made in decreasing morbidity and mortality from many 
pathogens with the use of antibiotics, and is a pressing public health concern worldwide, in upper-, 
middle-, and low-income nations alike [1,2].   Although AMR is not a new phenomenon, it is made more 
severe by the lack of new antibiotic agents being produced, and is particularly problematic in low- and 
middle-income countries. In addition to still battling infectious disease, these countries also face limited 
access and financial ability to buy newer, more effective antimicrobials [2,3].  
Many countries, including Rwanda, lack current information on antibiotic susceptibility profiles 
that would greatly aide clinicians and policy-makers. A review of available studies on this topic in Eastern 
Africa show that there is an increasing availability of publications from the mid-1970’s to the present, 
but that most reported research was conducted in Kenya and Ethiopia, with less (but still an increasing 
amount over time) from Uganda and Tanzania, and the least from Rwanda and Burundi [2]. Omulo et al. 
even go as far as to say that there is a general low prioritization of AMR in Sub-Saharan Africa, and that 
even in countries with higher number of publications like Kenya, the progress of research is slow relative 
to the global awareness of AMR in enteric bacteria [2]. The paucity of available data on trends of 
antibiotic sensitivity in Rwanda creates a need for descriptive studies on the landscape of AMR in this 
country.  
 Available published studies about AMR in Rwanda indicate the presence of antibiotic resistant 
strains of a number of different pathogens, including Streptococcus, Neisseria, and Shigella in the late 
1980s and early 1990s. In a 1993 study of 383 clinical isolates of Streptococcus pneumoniae in Kigali, 
Rwanda, researchers found that 2I % all isolates were confirmed as relatively resistant S. pneumoniae, 
called RRSP [4]. Specimens were collected  between 1984-1990 from 230 children and 153 adults at the 
Centre Hospitalier de Kigali with community-acquired infection. Isolates did not show a high level of 
resistance to penicillin G, but did exhibit resistance to chloramphenicol (3I % RRSP) and 6 % resistance in 
the penicillin susceptible strains (PSSP) [4]. Both RRSP and PSSP strains demonstrated doxycycline 
resistance, and all isolates remained fully susceptible to erythromycin. This study implied that penicillin 
G, ampicillin and chloramphenicol should not be used alone as empirical treatment for pneumococcal 
meningitis in patients in Rwanda [4]. Further information on drug classes and mechanisms of action and 
resistance is provided in the appendix.   
In Kigali specifically a study of antimicrobial resistance trends of Neisseria gonorrhea conducted 
from 1985-1993 tracked changes in antibiotic sensitivity for various drugs. Specimens were collected 
from men, women, and pre-pubertal girls reporting genital symptoms at the Centre Hospitalier de Kigali 
or the Centre Médico Social de Bilyogo. They found an increase in penicillinase-producing N. gonorrheae 
over the study period: these bacteria accounted for 39% during 1985-1991, but rose to 61% in 1992-
1993 [5]. They also identified plasmid-mediated resistance to tetracycline (TRNG) for the first time at the 
end of 1989, which increased from 2% of the isolates in 1990 to 50% by 1993 [5]. Overall, resistance to 
penicillin, thiamphenicol, and tetracycline was common in N. gonorrheae during 1985–1993 [5]. Another 
similar study was conducted on trends of N. gonorrhoeae resistance between 1986-2000, and found 
that while all gonococcal isolates were susceptible to ceftriaxone, ciprofloxacin, and spectinomycin (the 
recommended drugs of WHO), there were increasing levels of plasmid-mediated resistance in N. 
gonorrhoeae as well as chromosomal-mediated resistance [6]. Between April 1999-April 2000 samples 
were obtained from men with urethral syndromes and neonates with purulent conjunctivitis from the 
Centre Médico Social in Bilyogo, Rwanda. The results underscore that resistance levels to thiamphenicol 
and sulfamethoxazole/trimethoprim vary from country to country, and these drugs should not be 
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recommended without a reliable baseline susceptibility assessment, clinical trials, and regular 
surveillance [6]. A 1997 study on AMR of Shigella isolates in Kigali from 1983-1993 found that there was 
increasing frequency of resistance to multiple antibiotics [7]. They found that resistance to tetracycline 
was common in all Shigella species, and remained unchanged over time. However, they also 
documented increasing resistance to ampicillin, chloramphenicol, and trimethoprim among endemic 
Shigella spp., and increasing resistance to trimethoprim and nalidixic acid among S. dysenteriae Type 1 
isolates [7]. All isolates remained fully susceptible to norfloxacin and ciprofloxacin, but importantly, they 
identified several cases of combined AMR: 68% of S. flexneri, 78% of S. sonnei, 99% of S. dysenteriae 
Type 1 and 65% of S. boydii / S. dysenteriae Types 2-10 isolates that were resistant to more than one 
antibiotic [7]. This evidence emphasized the problem of multi-resistant Shigella isolates in Rwanda, and 
the need for consistent, continued monitoring of AMR and serotype distribution. 
A more recent study, from Muvunyi et al. 2011, provided further evidence that there is 
increasing resistance, and that continued use of first-line treatments may be contributing to resistance 
[8]. Samples from both inpatients and outpatients with urinary tract infections were collected from 
Butare University Hospital and Kigali University Hospital. The most common isolate from over 1,000 
urine cultures was E. coli. (60.7%), and it was found that the antibiotics commonly used in UTIs exhibit 
decreasing efficacy except Fosfomycin-trometamol and imipinem [8]. Risk factors associated with 
ciprofloxacin-resistant E. coli included use of ciprofloxacin or other antibiotics in the previous 6 months, 
and production of ESBL. Risk factors for ESBL positivity included the use of ciprofloxacin and third-
generation cephalosporin in the previous 6 months and being an inpatient [8]. These results suggest that 
alternatives are needed to address urinary tract infection in Rwanda, with Fosfomycin-trometamol 
proposed by the authors as a possible suitable therapy option.  
The most recent publication available, by Ogbuagu et al. (2015) documents high prevalence of 
AMR in Rwanda[3]. It was conducted to determine and describe the prevalence of AMR among 
pathogens associated with common infections in patients on the wards of the largest tertiary hospital in 
Rwanda. The study evaluated antibiotic sensitivity patterns of bacterial pathogens cultured from urine, 
blood, sputum, and wound swab specimens obtained over a 6-month period, and found that 31.4% and 
58.7% of Escherichia coli and Klebsiella isolates, respectively, were resistant to at least one of the third 
generation cephalosporins[3]. Eight percent of E. coli isolates were resistant to imipenem; 82% and 6% 
of Staphylococcus aureus strains were oxacillin- and vancomycin-resistant-respectively[3].  
Moving forward, it will be important to further classify the patterns in microbial resistance in 
Rwanda, in order to illustrate the landscape of AMR threats so that researchers, physicians, and policy 
makers may be better informed. The current study describes the time trends of antibiotic sensitivity for 
six different bacterial pathogens isolated from patients at King Faisal Hospital in Kigali, Rwanda. It also 
seeks to make inference about future patterns of drug resistance in the study setting, to guide 
physicians in their prescribing practices and provide baseline data for future interventions.  
 
Methods:  
Study Design 
This was a longitudinal study of the bacterial specimens (n=5296) collected by the internal medicine 
department at the King Faisal Hospital in Kigali, Rwanda, from January 1, 2009 to December 31, 2013.  
Data was collected on the frequency and antimicrobial sensitivity patterns of all cultures.  Samples with 
improper labeling and those with inadequate patient and specimen identifiers were excluded from the 
sample.  
 
Sample collection and processing  
Clinical specimens included urine, blood, sputum, and pus swab specimens from adult patients on 
internal medicine wards. Blood samples were collected and incubated into BD Bactec culture vials. 
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Urine, wound, and sputum cultures were collected in sterile containers. Laboratory materials, including 
sterile containers, antibiotic disks, and culture media, were obtained from Beckton, Dickinson, and 
Company (NJ).  
 
Blood samples were directly incubated in the BACTEC 9050 at 37°C for 5 days, and cultures were 
assessed daily for growth or presence of pathogens. Samples with bacterial growth were sub-cultured 
on appropriate media guided by gram stain results as follows: gram-positive cocci were plated on 
mannitol salt agar (MSA) and blood agar, whereas MacConkey agar and blood agar media were used for 
isolation of gram-negative bacilli. Additional identification of gram-positive cocci species was performed 
using catalase and coagulase tests. Identification of species of gram-negative bacilli was done by colony 
morphology and by using API 20 E strips (bioMerieux). 
 
Urine samples, after wet mount examination, were cultured on blood agar and cysteine lactose 
electrolyte-deficient (CLED). The number of colonies was counted after 18–24 hours of incubation at 
37°C. Specimens with > 105 CFU/mL urine were considered significant. Maximum duration of incubation 
was 48 hours. For wound swabs and sputum specimens, the gram stain morphology of principal 
pathogens dictated the selection of appropriate medium for culture, which was then incubated at 37°C 
for 24 hours. As with other specimens, identification of bacterial species was done using a combination 
of colony morphology, growth characteristics on selective media and by using API 20 E strips 
(bioMerieux) for Gram negative bacilli.  
 
Antibiotic susceptibility testing was performed by the Kirby Bauer disk diffusion method. The following 
antibiotic disks were used: ampicillin, 10 mg; ceftazidime, 30 mg; cefotaxime, 30 mg; ceftriaxone, 30 mg; 
cefalothin, 30 mg; cefuroxime, 30 mg; ciprofloxacin, 5 mg; amikacin, 30 mg; amoxicillin/clavulanic acid 
(amox/clav), 20/10 mg; erythromycin, 10 mg; gentamicin, 10 mg; imipenem, 10 mg; norfloxacin, 10 mg; 
penicillin, 10 units; oxacillin, 1 mg; piperacillin, 100 mg; and vancomycin, 30 mg. 
  
A suspension from growth on solid media plates was prepared by adding bacterial colonies into sterile 
distilled water until it approximated the same turbidity as the MacFarland turbidity standard 0.5. The 
resulting suspension was inoculated on Muller Hinton agar by using a sterile cotton swab. After this 
procedure, the antibiotic disks were added to the plate with at least 20 mm between each disk and 
subsequently incubated at 37°C for 18–24 hours; thereafter, interpretation of the diameter of inhibition 
was done according to 2012 Clinical and Laboratory Standards Institute (CLSI) guidelines. Quality control 
for the Kirby Bauer disk diffusion test was performed using three American Type Culture Collection 
(ATCC) strains: Escherichia coli ATCC 25922, S. aureus ATCC 25923, and Pseudomonas spp. ATCC 27853. 
Suspensions of the organisms were prepared as described above, and the inhibition diameter obtained 
was compared with the standard range expected for the ATCC strains. 
 
Data format: Data was aggregated annually, so that the proportion of bacteria from each source (urine, 
blood, sputum, and pus) susceptible to each drug was provided for each year.   
 
Statistical Analysis: 
Multiple approaches for identifying temporal trends were explored, although data format made the  
Mann-Kendall test and Wilcoxon rank-sum test inappropriate.  Ultimately, the Cochran-Armitage Trend 
Test and the Somers’ D Test [9] were used to test for trends in AMR across the 5 years. The “EXACT” 
statement of the Cochran-Armitage command produces exact p-values for the Cochran-Armitage test, 
indicating the probability that the dependent variable decreases as the independent variable increases, 
or that the dependent variable increases as the independent variable does. Also included in the output 
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is the Somers’ D(R|C), which measures the association treating the dependent (row) variable as the 
response and the independent (column) variable as a predictor. If the asymptotic 95% confidence limits 
do not contain 0, this indicates strong association (positive trend if the values are both greater than 0, 
and negative trend if the values are both less than 0).  
 
Results:  
Description of sample- Of all 5296 isolates collected between 2009 and 2013, 46.70% were of E. coli, 
18.41% were of Klebsiella spp., 5.91% were of Acinetobacter spp., 7.08% were of Pseudomonas spp., 
11.65% were of S. aureus, and 10.25% were of Enterococcus spp. (see Table 1).  
 
E. coli was found to be most sensitive to Colistin (98.6% ± 2.0), Imipenem (92.2% ± 11.0), and 
Nitrofurontoin (84.8% ± 3.7) over the course of 2009-2013. It was least sensitive to Ampicillin (14.8 ± 
3.7), Piperacillin (35.4 ± 10.1), and Amoxicillin+Clavulanate (36.0 ± 21.7), which are all Aminopenicillin 
drugs. However, there was large variation in sensitivity figures for Piperacillin and Amoxicillin. For 
further information about sensitivity trends for E. coli, see Supplemental Table 1a.   
 
Klebsiella spp. was tested by a majority of the antibiotics (16/23). It was found to be most sensitive to 
Colistin (99.8% ± 1.8), Imipenem (89.4% ± 10.8), and Norfloxacin (69.8% ± 14.3) over the study period. It 
was least sensitive to Piperacillin (18.2 ± 4.0), Amoxicillin+Clavulanate (24.6 ± 14.3), and Ceftriaxone 
(24.8 ± 18.9), all of which are ß-Lactam antibiotics. Further information about sensitivity trends for 
Klebsiella spp. can be found in Supplemental Table 1b.  
 
Acinetobacter spp. was most sensitive to Colistin (81.5% ± 20.2), Amikacin (59.2% ± 22.4), and Imipenem 
(45.2% ± 29.0). Notably, this species exhibited some of the lowest average sensitivity values, as only 
7.4% of Acinetobacter isolates from 2009-13 were sensitive to Ceftriaxone, and only 8.0% were sensitive 
to Cefotaxime, as compared to 24.8% and 29.0% in Klebsiella spp., respectively. This species was the 
least sensitive to Ceftriaxone (7.4 ± 4.0), Cefotaxime (8.0 ± 3.3), and Ceftazidime (15.4 ± 4.0), all 
Cephalosporin drugs. Further information about sensitivity trends for Acinetobacter spp. can be found in 
Supplemental Table 1c.  
 
Pseudomonas spp. was most sensitive to Colistin (97.0% ± 6.0), Imipenem (84.3% ± 31.5), and 
Ciprofloxacin (82.8 ± 4.6). Compared to the other species, Pseudomonas spp. exhibited relatively high 
levels of sensitivity—the lowest level of sensitivity was to Cefotaxime (49.4 ± 20.4), and this had a large 
standard deviation. Overall, this species showed low sensitivity to Cefotaxime, Pipercillin (77.0 ± 6.5), 
and Gentamicin (77.0 ± 9.4). Further information about sensitivity trends for Pseudomonas spp. can be 
found in Supplemental Table 1d.  
 
S. aureus was most sensitive to Vancomycin (100% all five years), Oxacillin (97.8% ± 1.10), and 
Gentamicin (87.2% ± 6.46). This pathogen showed relatively high levels of sensitivity, as only 3 of the 9 
antibiotic groups tested showed sensitivity percentages of less than 70% during the period 2009-13. It 
was least sensitive to Ampicillin (20.0 ± 6.3), Amoxicillin+Clavulanate (40.6 ± 23.0), and Erythromycin 
(64.0 ± 10.7). Further information about sensitivity trends for S. aureus can be found in Supplemental 
Table 1e.   
 
Enterococcus spp. shows greatest susceptibility to Vancomycin (99.4± 1.3), Amoxicillin + Clavulanate 
(89.0%± 6.2), and Ampicillin (82.6% ± 1.8) during the years 2009-13. This species showed the greatest 
sensitivity to Ampicillin and to Amoxicillin of any of the included species. During the five-year period, it 
was least sensitive to Penicillin (26.8 ± 12.7), Gentamicin (27.0% ± 6.0), and Levofloxacin (54.6 ± 18.4).  
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Trend Determination- The results of the Cochran-Armitage and Somers’ D tests are shown in Figure 1. 
The majority of the pathogens (4 of 6) were not tested with Erythromycin, Cephalexin, Oxacillin, 
Vancomycin, or Penicillin. When annual bacterial susceptibility testing did occur for a pathogen, the 
most likely pattern of sensitivity across the five year period was ‘No Trend’ (41/61= 67.21%). Of the 
remaining 20 groups, the majority (17/20) were characterized as ‘Negative Trend’, which indicates 
decreasing antibiotic sensitivity, or increasing AMR. Only 3 groups were classified as having a ‘Positive 
Trend’: Acinetobacter spp./Colistin, S. aureus/Erythromycin, and Enterococcus spp./Vancomycin.   
 
Across the six bacterial groups, E. coli has the greatest number of ‘Negative Trend’ groups (n=5), 
followed by Klebsiella spp. and Acinetobacter spp., with each having  4 ‘Negative Trend’ groups. E. coli 
had decreasing sensitivity, or increasing resistance, to Gentamicin, Nalidixic Acid, Pipercillin, Imipenem, 
and Colistin. There was no trend for Ampicillin, Amoxicillin+Clavulanate, Norfloxacin, Ciprofloxacin, 
Cefuroxime, Cotrimoxazole, or Nitrofurantoin. Figure 2a depicts the five antibiotics that had negative 
trends over time for E. coli. Figure 2b depicts E. coli sensitivity response to all antibiotics.  
 
Klebsiella spp. had 4 ‘Negative Trend’ groups, indicating decreasing sensitivity to 
Amoxicillin+Clavulanate, Ciprofloxacin, Pipercillin, and Imipenem. There was no trend for Gentamicin, 
Nalidixic Acid, Norfloxacin, Cefuroxime, Cotrimoxazole Nitrofurantoin, Amikacin, Cefotaxime, 
Ceftriaxone, Levofloxacin, Ceftazidime, or Colistin. Figure 3a depicts the four antibiotics that had 
negative trends over time for Klebsiella spp. Figure 3b depicts Klebsiella spp. response to all antibiotics.  
 
Acinetobacter spp. also had 4 ‘Negative Trend’ groups, indicating decreasing sensitivity to Ciprofloxacin, 
Ceftriaxone, Levofloxacin, and Imipenem. There was no trend for Amikacin, Cefataxime, or Ceftazidime.  
Figure 4a depicts the four antibiotics that had negative trends over time for Acinetobacter spp. Figure 
4b. depicts Acinetobacter spp. response to all antibiotics.  
 
Importantly, Imipenem can be seen as a recurring entity in each of Figures 2a, 3a, and 4a, indicating that 
it is decreasing in efficacy yearly against multiple bacterial pathogens, and requires further study. 
Amongst the group of 23 antibiotics tested against the different bacterial species, Piperacillin and 
Imipenem registered the greatest frequency of ‘Negative Trend’ indications. Plotting the average 
susceptibility proportion for all isolates in each year for Imipenem and Piperacillin yields a graph 
depicting negative trends over time for Imipenem and Piperacillin, respectively, as can be seen in Figure 
5.   
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Results:  
Table 1.  Average annual antimicrobial sensitivity (%) and corresponding standard deviation of all isolates collected from King Faisal Hospital 
between 2009-2013.  
  
 Bacterial species 
Antimicrobial Agent 
Escherichia 
coli 
(n= 2473) 
Klebsiella 
spp. 
(n= 975) 
Acinetobacter 
spp. 
(n=313) 
Pseudomonas 
spp. 
(n= 375) 
Staphylococcus 
aureus 
(n= 617) 
Enterococcus 
spp. 
(n= 543) 
Ampicillin 14.8 (3.7) N/A N/A N/A 20.0 (6.3) 82.6 (1.8) 
Amoxicillin +Clavulanate 36.0 (21.7) 24.6 (14.3) N/A N/A 40.6 (23.0) 89.0 (6.2) 
Gentamicin 74.0 (2.6) 51.8 (3.8) N/A 77.0 (9.4) 87.2 (6.5) 27.0 (6.0) 
Nalidixic Acid 51.6 (5.1) 54.6 (12.0) N/A N/A N/A N/A 
Norfloxacina 66.4 (2.9) 69.8 (14.3) N/A N/A N/A N/A 
Ciprofloxacin 50.8 (9.7) 49.6 (5.0) 18.4 (1.8) 82.8 (4.6) 85.0 (9.7) N/A 
Cefuroxime 75.2 (6.0) 48.4 (17.2) N/A N/A N/A N/A 
Piperacillin 35.4 (10.1) 18.2 (4.0) N/A 77.0 (6.5) N/A 70.4 (32.2) 
Cotrimoxazole 28.5 (3.4) 28.4 (6.2) N/A N/A 72.0 (15.8) N/A 
Nitrofurontoina 84.8 (3.7) 47.8 (8.6) N/A N/A N/A N/A 
Amikacin N/A 64.8 (13.4) 59.2 (22.4) 76.8 (16.3) N/A N/A 
Cefotaxime N/A 29.0 (8.7) 8.0 (3.3) 49.4 (20.4) N/A N/A 
Ceftriaxone N/A 24.8 (18.9) 7.4 (4.0) N/A N/A N/A 
Levofloxacin N/A 46.0 (0.0)b 22.6 (12.7) N/A N/A 54.6 (18.4) 
Ceftazidime N/A 31.6 (12.5) 15.4 (4.0) 81.0 (11.4) N/A N/A 
Imipenem 92.2 (11.0) 89.4 (10.8) 45.2 (29.5) 84.3 (31.5)b N/A N/A 
Chloramphenicol N/A N/A N/A N/A N/A 59.8 (10.6) 
Colistin 98.6 (2.0) 99.8 (1.8) 81.5 (20.2)b 97.0 (6.0)b N/A N/A 
Erythromycin N/A N/A N/A N/A 64.0 (10.7) N/A 
Cephalexin N/A N/A N/A N/A 86.4 (5.7) N/A 
Oxacillin N/A N/A N/A N/A 97.8 (1.1) N/A 
Vancomycin N/A N/A N/A N/A 100 (0.0) 99.4 (1.3) 
Penicillin N/A N/A N/A N/A N/A 26.8 (12.8)b 
 
a For urine isolates only 
b Less than 5 years of data; only groups with at least 3 years were included. 
N/A: Not Applicable; pathogen was not treated with this antibiotic. 
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Figure 1. Results of trend determination from the years 2009-2013 from the Cochran-Armitage and Somers’ D tests.  
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Figure 1. The above details the results of the Cochran-Armitage test and Somers’ D test for time trend, examining the trend in bacterial 
susceptibility to specific antibiotics across the time period 2009-2013.  
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Figure 2a. E. coli response to antibiotics with negative susceptibility trend over time.  
 
 
0
10
20
30
40
50
60
70
80
90
100
2009 2010 2011 2012 2013
P
r
o
p
o
r
t
i
o
n
 
I
s
o
l
a
t
e
s
 
S
u
s
c
e
p
t
i
b
l
e
 
(
%
)
Years
E. coli response to selected antibiotics, 2009-13 
Gentamicin Nalidixic Acid Pipercillin Imipenem Colistin
 14
Figure 2b. E. coli response to all antibiotics, 2009-2013 
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Figure 3a. Klebsiella spp. response to antibiotics with negative susceptibility trend over time.  
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Figure 3b. Klebsiella spp. response to all antibiotics, 2009-2013 
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Figure 4a. Acinetobacter spp. response to antibiotics with negative susceptibility trend over time. 
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Figure 4b. Acinetobacter spp. response to all antibiotics, 2009-2013 
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Figure 5. Imipenem and Piperacillin susceptibility.  Graph shows the average susceptibility amongst all isolates per year during the period 2009-
13.  
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Discussion:  
Several studies have illustrated the growing threat of AMR in Sub-Saharan Africa, and there is a need for 
studies reporting on prevalence of resistant pathogens and the yearly trends of specific antimicrobial 
agents. This work sought to serve this need by examining the patterns of AMR for six unique bacterial 
pathogens, including Escherichia coli, Klebsiella species, Acinetobacter species, Pseudomonas species, 
Staphylococcus aureus, and Enterobacter species. These common bacterial isolates originated from 
clinical specimens of patients in the internal medicine wards of King Faisal Hospital in Kigali, Rwanda. 
Antibiotic sensitivity was recorded for a variety of pathogen-antibiotic groups during the five-year period 
from January 2009-December 2013.   
 
Univariate statistical analysis revealed that the majority of bacterial isolates were E. coli, and the 
minority were Acinetobacter spp. This supports other recent studies from similar populations in Rwanda 
(3,8).  Among all gram-negative isolates, Colistin exhibited the highest efficacy, although with high yearly 
variability in Acinetobacter spp. (81.5% average annual antibiotic sensitivity, with 20.21% standard 
deviation). As shown in Supplemental Tables 1a-d, sensitivity to Colistin remained relatively consistent 
throughout the time period. Imipenem was the second-most effective antibiotic amongst the gram-
negative species, exhibiting antibiotic susceptibility proportions of 80% or greater in each of the species 
besides Acinetobacter spp., where is only yielded an average annual susceptibility proportion of 45.2%. 
Notably, Acinetobacter spp. consistently has the lowest average antibiotic sensitivity figures of all the 
gram-negative pathogens for each drug tested. This finding should be confirmed by further study. 
Among all gram-positive organisms, the antibiotic with the greatest overall effect was Vancomycin. It 
achieved 100% bacterial sensitivity for all five years for S. aureus, and a mean susceptibility of 99.4% 
(standard deviation, 1.34%) for Enterococcus spp. This is encouraging for the treatment of gram-positive 
species, as it suggests that there are still drugs with high sensitivity patterns, and potential for clinical 
longevity. Contrary to another recent study [3], we did not identify any Vancomycin resistance for 
Staphylococcus aureus. We also found that S. aureus was, on average, 97.8% sensitive to Oxacillin, or 
less than 3% resistant, in stark contrast to the finding that 82% of S. aureus strains were Oxacillin-
resistant [3].  However, our results do corroborate the finding in the work of Nitrenganya et al. [3] that 
E. coli and Klebsiella isolates are at least 30% and 60% resistant, respectively, to a third-generation 
cephalosporin (Cefotaxime, Ceftriaxone). Similar to their findings, E. coli showed 8% resistance to 
Imipenem in the current study.    
 
An analysis of antibiotic sensitivity over time indicated that the majority of bacterial groups yielded no 
trend. However, there were 17 negative trends identified, and 3 positive trends. The majority of 
negative susceptibility trends over time were identified in E. coli, Klebsiella spp., and Acinetobacter spp.  
Interestingly, Imipenem was the antibiotic that exhibited negative temporal trends for all three of these 
species, and it was found to have decreasing effectiveness over time for four species. 
Similarly, Piperacillin showed a negative trend for three bacterial species, including E. coli, Klebsiella 
spp., and Enterococcus spp. (Figure 3).  
 
This study had several limitations. Importantly, the dataset itself did not include susceptibility testing for 
all bacteria against all antiobiotics potentially used for treatment. Statistical variation was lost because 
of this limitation and because the results of various antibiotic susceptibility tests throughout a given year 
were collapsed into a single summary score.  Future studies should attempt to capture a complete 
record of the multiple individual tests for each antibiotic-pathogen combination. Such data would 
provide more precise and nuanced information to inform clinicians and public health professions on 
important trends on the profile bacterial species’ sensitivity responses to each antibiotic. Additionally, as 
only one data point was provided per year, trend analyses of only five data points per group precludes 
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drawing conclusive interpretations of drug sensitivity trends and our ability to inform policy 
recommendations.   
 
Conclusions: 
This study described trends of AMR in the King Faisal Hospital in Kigali, Rwanda. However, limitations to 
obtaining complete data regarding temporal trends of AMR in Rwanda, limited conclusive 
interpretations of our results. It is imperative that regular, consistent antibiotic sensitivity test be 
conducted on the common clinical isolates of patients. More complete data over a longer timeframe will 
provide more robust estimates of AMR and alert us to emerging resistant strains of bacteria. Further 
research might focus on the future of Imipenem and Piperacillin amongst gram-negative isolates in this 
clinical setting.  
 
 
Reference:  
 
1. CDC (2014) Antibacterial / Antimicrobial Resistance. Centers for Disease Control and Prevention. 
2. Omulo S, Thumbi SM, Njenga MK, Call DR (2015) A review of 40 years of enteric antimicrobial 
resistance research in Eastern Africa: what can be done better? Antimicrob Resist Infect Control 
4: 1. 
3. Ntirenganya C, Manzi O, Muvunyi CM, Ogbuagu O (2015) High Prevalence of Antimicrobial Resistance 
Among Common Bacterial Isolates in a Tertiary Healthcare Facility in Rwanda. Am J Trop Med 
Hyg. 
4. Bogaerts J, Lepage P, Taelman H, Rouvroy D, Batungwanayo J, et al. (1993) Antimicrobial susceptibility 
and serotype distribution of Streptococcus pneumoniae from Rwanda, 1984-1990. J Infect 27: 
157-168. 
5. Bogaerts J, Van Dyck E, Mukantabana B, Munyabikali JP, Martinez Tello W (1998) Auxotypes, serovars, 
and trends of antimicrobial resistance of Neisseria gonorrhoeae in Kigali, Rwanda (1985-93). Sex 
Transm Infect 74: 205-209. 
6. Van Dyck E, Karita E, Abdellati S, Dirk VH, Ngabonziza M, et al. (2001) Antimicrobial susceptibilities of 
Neisseria gonorrhoeae in Kigali, Rwanda, and trends of resistance between 1986 and 2000. Sex 
Transm Dis 28: 539-545. 
7. Bogaerts J, Verhaegen J, Munyabikali JP, Mukantabana B, Lemmens P, et al. (1997) Antimicrobial 
resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing 
frequency of multiple resistance. Diagn Microbiol Infect Dis 28: 165-171. 
8. Muvunyi CM, Masaisa F, Bayingana C, Mutesa L, Musemakweri A, et al. (2011) Decreased 
susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from 
urinary tract infections in Rwanda: need for new antimicrobial guidelines. Am J Trop Med Hyg 
84: 923-928. 
9. (2015) Base SAS (R) 9.2 Procedures Guide. Statistical Procedures. 3 ed: SAS. 
10. Engleberg CN, DiRita V (2013) Biological Basis for Antibacterial Action. In: Engleberg CN, DiRita V, 
Dermody TS, editors. Schaechter's Mechanisms of Microbial Disease. 5th ed. Baltimore, MD: 
Wolters Kluwer/Lippincott Williams & Wilkins. pp. 55-65. 
 
 
 
 
 
 22
APPENDIX 
 
Information about drug classes and mechanism of action 
(1) ß-Lactam Antibiotics: Penicillins, Cephalosporins, and Carbapenems 
Mechanism of action: Beta-lactam antibiotics affect the biosynthesis of the murein layer of the bacterial cell wall. Traditionally these 
antibiotics have been effective because no analogous structure exists in mammalian cells, which means only bacteria are targeted, 
and host cells are protected [10]. The chemical structure of these antibiotics contains a ß-lactam ring. Certain side chains located on 
the ß-lactam ring allow the drugs to permeate the outer membrane of Gram-negative bacteria; once they have entered, they kill the 
organism[10]. 
Mechanism of Resistance: The modification of the drug by bacteria inactivates it. ß-lactamase enzymes hydrolyze the ß-lactam ring.  
Examples used in this study:  
• Ampicillin:  Part of Aminopenicillin family; most effective against gram-positive species S. pneumoniae, S. pyogenes, S. 
aureus, and some Enterococcus spp.; gram-negative species N. meningitidis, H. influenzae, and some Enterobacteriacea.  
• Amoxicillin: Aminopenicillin family; for use against acute otitis media, UTIs, Lyme Disease, S. pneumoniae.  
• Cefalexin: First-generation Cephalosporin; for use against Gram-positive and some Gram-negative species.  
• Cefotaxime: Third-generation Cephalosporin; for use against S. aureus, S. pneumoniae, Klebsiella spp., Enterobacter spp. and 
others 
• Cefuroxime: Second-generation Cephalosporin; for use against Gram-positive bacteria 
• Ceftriaxone: Third-generation Cephalosporin; broad-spectrum activity against Gram-positive bacteria and extended coverage 
of Gram-negative bacteria compared to second-generation drugs.  
• Ceftazidime: Third-generation Cephalosporin; activity against Gram-positive and Gram-negative species.  
• Imipenem: First-generation Carbapenem; given intravenously; broad-spectrum use for Gram-positive and Gram-negative 
pathogens; important for use against Enterococcus spp. and P. aeruginosa 
• Oxacillin: Penicillin family; resistant to Penicillinases; for use against S. aureus and other Penicillinase-producing organisms 
• Piperacillin: Ureidopenicillin family; given via intravenous or intramuscular injection; for use against Pseudomonas spp.  
 
(2) Anti-ribosomal Antibiotics: Aminoglycosides and Macrolides 
Mechanism of action: This second-largest class of antibiotics is effective because of structural differences in bacterial and eukaryotic 
ribosomes [10]. These drugs penetrate the outer membrane of Gram-negative organisms, then associate with a two-stage active 
transport system in the cell membrane. Finally, they bind the 30S ribosome subunit to inhibit protein synthesis and increase 
miscoding by the ribosomes, and ultimately increase the production of “nonsense” proteins that lead to the cell’s death [10].  
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Mechanism of Resistance: The modification of the drug by the bacterial R-plasmid-encoded enzyme, which results in reduced affinity 
for the ribosome and reduced transport into the cell [10].  
Examples used in this study:  
• Gentamicin: Aminoglycoside family; for use against Gram-negative species including E. coli 
• Amikacin: Aminoglycoside family; used to treat multi-drug resistant Gram-negative bacteria like Pseudomonas aerugrinosa, 
Acinetobacter spp. and Enterobacter spp. 
• Erythromycin: Macrolide family; typically prescribed for people with penicillin allergy; for use mainly against Gram-positive 
species, with limited Gram-negative use.  
 
(3) Anti-folate Antibiotics: Sulfonamides 
Mechanism of action: Capitalizes on the different ways eukaryotic cells and bacteria synthesize and use folic acid [10]. Humans 
require preformed folic acid, and are therefore unaffected by sulfonamides, which inhibit the synthesis of this compound. On the 
contrary, most bacteria that make folic acid lack a system for the uptake of preformed folic acid, so they die without it [10].  
Mechanism of Resistance: Modification of the drug target, dihydropteroate synthase, makes the drug inactive.  
Examples used in this study:  
• Cotrimoxazole: Broad-spectrum drug effective against Acinetobacter spp., E. coli, Klebsiella spp., S. aureus, and many others 
(not to include Enterococcus spp. Or Pseudomonas spp.)    
 
(4) Quinolones and Fluoroquinolones 
Mechanism of action: This drug class works by inhibiting the action of bacterial topoisomerases—in Gram-positive bacteria, DNA 
gyrase, and in Gram-negative bacteria, topoisomerase IV. Bacteria are killed when topoisomerases are trapped while cutting DNA, 
which creates double-strand breaks in the bacterial chromosome [10].  
Mechanism of Resistance: Mutations in the genes encoding DNA gyrase and topoisomerase IV cause reduced binding of the drugs.  
Examples used in this study:  
• Nalidixic Acid: Primarily for use against Gram-negative species like E. coli, Enterobacter spp., and Klebsiella spp. 
• Norfloxacin: Second-generation Fluoroquinolone family; for use against bacteria causing urinary tract infections, including E. 
coli 
• Ciprofloxacin: Second-generation Fluroquinolone; for use against Gram-negative species including E. coli, Klebsiella spp., P. 
aeruginosa, as well as Gram-positive species such as Enterococcus faecalis, S. aureus.  
• Levofloxacin: Third-generation Fluroquinolone; for use against Gram-positive and Gram-negative species 
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(5) Nitrofurantoin:  
Mechanism of action: This drug works by damaging bacterial DNA via nitrofuran reductase to create intermediates that attack 
ribosomal proteins, DNA, pyruvate metabolism, and other important cellular components [10]. For use against: E.coli, 
Staphylococcus spp., Klebsiella spp.  
Mechanism of Resistance: Resistance may be chromosomal or plasmid-mediated, and involved inhibition of nitrofuran reductase.  
 
(6) Chloramphenicol: 
Mechanism of action: Slows growth of bacteria by inhibiting protein synthesis, via interference with protein chain elongation. It 
inhibits the peptidyl transferase activity of the bacterial ribosome [10]. For use against: Gram-positive and Gram-negative species, 
and most anaerobic species.  
Mechanism of Resistance: Resistance to this drug occurs by three different ways—reduced membrane permeability; mutation of 50S 
ribosomal subunit, and elaboration of chloramphenicol acetyltransferase.   
 
(7) Colistin: 
Mechanism of action: This polymyxin antibiotic has both hydrophilic and lipophilic portions, which help to solubilize the bacteria 
cytoplasmic membranes, like a detergent [10].  
For use against: highly-resistant Gram-negative infections.  
Mechanism of Resistance: Resistance is rare, but has been described (cite this). Mechanism is unclear.  
 
(8) Vancomycin: 
Mechanism of action: This drug works by inhibiting proper cell wall formation in Gram-positive bacteria [10]. For use against 
Enterococcus spp., MRSA 
Mechanism of Resistance: Resistance can be caused by either a change in the binding site in the peptidoglycan target, or restricted 
access to drug target.  
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Supplemental Table 1a.  Antimicrobial susceptibilities of Escherichia coli isolates collected between 2009-2013  
 
 No. of Isolates Tested 
Antimicrobial Agent 
2009 
(n= 415) 
2010 
(n= 429) 
2011 
(n= 469) 
2012 
(n= 579) 
2013 
(n= 581) 
Ampicillin 14 11 21 14 14 
Amoxicillin +Clavulanate 43 62 48 14 13 
Gentamicin 76 76 73 75 70 
Nalidixic Acid 59 51 53 50 45 
Norfloxacina 70 66 67 67 62 
Ciprofloxacin 48 52 65 51 38 
Cefuroxime 84 68 72 77 75 
Pipercillin 51 30 40 30 26 
Cotrimoxazole 25 30 28 25 21 
Nitrofurontoina 86 80 87 82 89 
Amikacin nt nt nt nt 97 
Cefataxime nt nt nt nt 80 
Ceftriaxone nt nt nt nt 80 
Levofloxacin nt nt nt nt 43 
Ceftazidime nt nt nt nt 80 
Imipenem 100 100 100 77 84 
Chloramphenicol nt nt nt nt 57 
Colistin 100 100 100 96 97 
      
a for urine isolates only 
nt: The pathogen was not tested with this antibiotic at this time point.  
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Supplemental Table 1b.  Antimicrobial susceptibilities of Klebsiella spp. isolates collected between 2009-2013  
 
 
a for urine isolates only 
nt: The pathogen was not tested with this antibiotic at this time point.  
 
 
 
 
 
 
 
 
 
 
 No. of Isolates Tested 
Antimicrobial Agent 
2009 
(n= 138) 
2010 
(n= 193) 
2011 
(n= 219) 
2012 
(n= 235) 
2013 
(n= 190) 
Amoxicillin +Clavulanate 31 44 26 7 15 
Gentamicin 56 55 48 48 52 
Nalidixic Acid 62 70 46 40 55 
Norfloxacina 89 79 58 55 68 
Ciprofloxacin 50 58 46 48 46 
Cefuroxime 78 45 33 44 42 
Pipercillin 20 21 13 22 15 
Cotrimoxazole 22 37 23 31 29 
Nitrofurontoina 49 46 41 41 62 
Amikacin 81 52 54 60 77 
Cefataxime 24 44 29 23 25 
Ceftriaxone 15 26 15 11 57 
Levofloxacin nt nt 46 46 46 
Ceftazidime 21 45 27 20 45 
Imipenem 100 97 94 81 75 
Chloramphenicol nt nt nt nt 4 
Colistin 100 100 100 96 100 
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Supplemental Table 1c.  Antimicrobial susceptibilities of Acinetobacter spp. isolates collected between 2009-2013  
 
 No. of Isolates Tested 
Antimicrobial Agent 
2009 
(n= 33) 
2010 
(n= 58) 
2011 
(n= 69) 
2012 
(n= 94) 
2013 
(n= 59) 
Ciprofloxacin 25 23 17 13 14 
Amikacin 73 32 40 66 85 
Cefataxime 11 5 12 5 7 
Ceftriaxone 13 9 8 4 3 
Levofloxacin 42 27 13 21 10 
Ceftazidime 13 18 21 14 11 
Imipenem 86 64 31 33 12 
Colistin nt 85 52 93 96 
      
a for urine isolates only 
nt: The pathogen was not tested with this antibiotic at this time point.  
 
Supplemental Table 1d.  Antimicrobial susceptibilities of Pseudomonas spp. isolates collected between 2009-2013  
 
 No. of Isolates Tested 
Antimicrobial Agent 
2009 
(n= 25) 
2010 
(n= 52) 
2011 
(n= 94) 
2012 
(n= 118) 
2013 
(n= 86) 
Gentamicin 65 78 91 77 74 
Ciprofloxacin 80 86 89 81 78 
Pipercillin 71 81 83 81 69 
Amikacin 88 51 93 74 78 
Cefataxime 82 35 56 32 42 
Ceftazidime 65 93 89 84 74 
Imipenem nt 100 100 100 37 
Colistin nt 100 100 100 88 
 
a for urine isolates only 
nt: The pathogen was not tested with this antibiotic at this time point.  
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Supplemental Table 1e.  Antimicrobial susceptibilities of Staphyloccocus aureus isolates collected between 2009-2013  
 
 No. of Isolates Tested 
Antimicrobial Agent 
2009 
(n=118 ) 
2010 
(n= 140) 
2011 
(n= 102) 
2012 
(n= 135) 
2013 
(n= 122) 
Ampicillin 12 20 29 22 17 
Amoxicillin +Clavulanate 51 20 76 30 26 
Gentamicin 79 82 94 89 92 
Ciprofloxacin 86 83 71 98 87 
Cotrimoxazole 67 76 65 97 55 
Erythromycin 47 71 73 69 60 
Cephalexin 79 88 88 83 94 
Oxacillin 96 98 98 99 98 
Vancomycin 100 100 100 100 100 
      
a for urine isolates only 
nt: The pathogen was not tested with this antibiotic at this time point.  
 
Supplemental Table 1f.  Antimicrobial susceptibilities of Enterococcus spp. isolates collected between 2009-2013  
 
 No. of Isolates Tested 
Antimicrobial Agent 
2009 
(n= 56) 
2010 
(n= 113) 
2011 
(n= 85) 
2012 
(n= 157) 
2013 
(n= 132) 
Ampicillin 80 85 82 83 83 
Amoxicillin +Clavulanate 80 96 91 86 92 
Gentamicin 24 27 26 21 37 
Pipercillin 77 95 91 74 15 
Levofloxacin 29 64 73 65 42 
Chloramphenicol 65 46 69 51 68 
Vancomycin 97 100 100 100 100 
Penicillin nt 45 26 17 19 
 
a for urine isolates only 
nt: The pathogen was not tested with this antibiotic at this time point.  
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Supplemental Figure 1a.  
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Supplemental Figure 1b.  
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Supplemental Figure 1c.  
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